Trial
NCT05218408
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Celularity Incorporated
Collaborators
—
Condition
Astrocytoma, Grade IV
Intervention
CYNK-001 systemic and Intra cavity administration
Why stopped
No participants were enrolled. Study was withdrawn prior to treatment initiation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-08